转换为抗程序性细胞死亡蛋白1(抗PD-1)固定剂量方案:经济影响如何?
该研究基于Gustave Roussy数据库与法国国家医院出院数据库的真实世界数据,分析纳武利尤单抗和帕博利珠单抗固定剂量方案在法国的预期年度预算影响。结果显示固定剂量方案每输注纳武利尤单抗和帕博利珠单抗分别增加284欧元和1287欧元成本,法国全国2017年年度预算影响估计为55 162 211欧元。
要点
- 固定剂量方案参照体重高于癌症患者实际平均体重,可能对医疗系统产生重大经济影响。
- 每输注纳武利尤单抗固定剂量较按体重给药增加284欧元(95%CI 241-327)。
- 每输注帕博利珠单抗固定剂量较按体重给药增加1287欧元(95%CI 1200-1373)。
核心结论
- 固定剂量方案的体重参照值不反映接受癌症治疗患者的准确平均体重,可能对医疗系统产生重大经济影响。
研究设计与样本
- 预算影响分析,使用Gustave Roussy数据库和法国国家医院出院数据库的真实世界数据,纳入在欧洲批准固定剂量方案之前接受纳武利尤单抗或帕博利珠单抗治疗的患者。
- 主要结局为固定剂量方案在法国的预期年度预算影响。
主要发现
- 2018年1月至4月,本机构共实施978次抗PD-1输注,包括103例患者的560次纳武利尤单抗输注和125例患者的418次帕博利珠单抗输注,主要治疗肺癌和黑色素瘤。
- 固定剂量导致的每输注平均额外成本为纳武利尤单抗284欧元(95%CI 241-327),帕博利珠单抗1287欧元(95%CI 1200-1373)。
- 在Gustave Roussy,2018年年度额外成本分别为纳武利尤单抗477 120欧元(95%CI 404 880-549 360)和帕博利珠单抗1 613 898欧元(95%CI 1 504 800-1 721 742)。
- 在法国国家层面,2017年预期年度预算影响估计为55 162 211欧元。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab and pembrolizumab were initially developed using weight-based regimen doses. Recently, fixed-dose regimens were commercialised with reference weights higher than the accurate weight of patients with cancer in routine practice. This may have important economic consequences for healthcare systems. MATERIAL AND METHODS: Budget impact analysis was performed using real-world data both from Gustave Roussy database and the French National Hospital Discharge database and including patients treated with either nivolumab or pembrolizumab at Gustave Roussy and in France before the approval of fixed-dosing regimens in Europe. Main outcome is the expected annual budget impact of fixed-dosing regimens in France. RESULTS: From January to April 2018, 978 perfusions of anti-programmed cell death protein 1 were administered at our institution including 560 perfusions of nivolumab in 103 patients and 418 perfusions of pembrolizumab in 125 patients mainly treated for lung cancer and melanoma. The mean extra cost attributable to flat doses would have amounted to €284 (95% confidence interval [CI]: 241-327) per infusion of nivolumab and to €1287 (95% CI: 1200-1373) per infusion of pembrolizumab. Annually, at Gustave Roussy, it would represent an extra cost of € 477 120 (95% CI: 404 880-549 360) and €1 613 898 (95% CI: 1 504 800-1 721 742), respectively, for the year 2018. At the French national level, the expected annual budget impact is estimated at €55 162 211 for the year 2017. CONCLUSIONS: Weight references for fixed-dose regimens do not reflect the accurate mean weight of patients under cancer treatment and are likely to have substantial economic impact for healthcare systems.
引用
- Bayle A, Besse B, Annereau M, et al. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? Eur J Cancer. 2019. PMID: 30965212. doi:10.1016/j.ejca.2019.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。